When Do Drugs Go Generic? Patent Cliffs Explained

A drug can face generic competition once its patents and any FDA-granted exclusivity periods expire, which the FDA tracks in a public database called the Orange Book. This typically happens 10 to 15 years after a drug launches, though it varies widely by drug. Comparing prescription prices on a still-brand-only drug versus one with generic competition shows how big the difference can be once that window opens. Prices vary by pharmacy, location, quantity, and eligibility.

Two separate clocks: patents and FDA exclusivity

There are two distinct legal protections that delay generic competition, and they run on different clocks.

Patents are granted by the U.S. Patent and Trademark Office, typically lasting 20 years from the filing date, which usually happens years before the drug is even approved for sale. By the time a drug reaches the market, much of that 20-year clock has already elapsed during clinical development.

FDA exclusivity is separate from patents and is granted automatically upon approval for certain categories, such as 5 years of exclusivity for a new chemical entity or 3 years for certain new uses of an already-approved drug (FDA). Exclusivity exists independent of whatever patents the company holds, and generics cannot launch until both the relevant patents and any applicable exclusivity periods have run out or been successfully challenged.

Where to actually check the timeline

The FDA's Orange Book is the official public reference for approved drug products along with the patents and exclusivities associated with each one (FDA). Searching a drug's application number in the Orange Book shows any listed patents and their expiration dates, as well as exclusivity codes and end dates. The FDA notes that because patents can be listed for many different reasons, including formulation or method-of-use patents, the Orange Book alone cannot tell you with certainty when a generic will actually launch, only the protections currently on record (FDA).

What a "patent cliff" actually looks like

A patent cliff describes the period when a blockbuster drug's core protections lapse and several generic manufacturers are positioned to enter the market at once, often triggering a steep, rapid decline in the brand's price and sales. This differs from a slow, single-competitor entry. When multiple manufacturers launch generics around the same time, price competition tends to be much sharper. FDA analysis has found that having multiple approved generic competitors is associated with substantially larger price reductions than having just one (FDA).

Common ways brand companies extend the timeline

None of the following are illegal on their own, but they are common reasons a drug's generic entry gets pushed later than expected:

• Follow-on patents covering a new formulation, delivery device, or combination product, even after the original core patent expires.
• Pediatric exclusivity, an additional 6 months awarded when a company studies the drug in children at the FDA's request.
• Orphan drug exclusivity, up to 7 years for drugs treating rare diseases.
• Patent litigation settlements, where a brand and a generic manufacturer agree on a specific date for generic entry, sometimes earlier than full patent expiration but later than a generic company might otherwise have achieved through litigation.

Patent cliff timeline: typical protections at a glance

Why this matters for your own prescriptions

If you take a brand-name drug that has no generic yet, it is worth periodically checking whether that has changed, since even the first generic entering the market can meaningfully lower prices, and additional competitors lower them further over time. In the meantime, ask your pharmacist whether a therapeutic alternative already has generic versions available, since a clinically similar drug in the same class might already be off-patent even if your specific medication is not. Search your medication on BetterBuyRx to see current pricing and whether lower-cost options exist near you.

What you can do while waiting for a generic

• Ask your pharmacist for the drug's generic status and whether any generic manufacturer has recently launched a competing product.
• Ask your prescriber about therapeutic alternatives in the same drug class that may already have generic versions, without changing your treatment plan on your own.
• Look into manufacturer copay cards for the brand-name drug while no generic exists, since these can lower your out-of-pocket cost in the meantime.
• Compare pharmacy cash prices, since even brand-name drug prices can differ from pharmacy to pharmacy before any generic is available.

Compare prescription prices on BetterBuyRx to track how a medication's cost changes as competition increases, and check back periodically if you are waiting on a generic version.

A note on biologics and biosimilars

Biologic drugs, which are made from living organisms rather than chemically synthesized, follow a somewhat different and often longer pathway to lower-cost competition. Instead of a generic, a biologic faces competition from a biosimilar, a highly similar version approved through a separate FDA pathway. Biosimilar competition has been slower to develop in the United States than traditional generic competition, though the number of approved biosimilars has grown substantially in recent years. If you take an expensive biologic medication, ask your pharmacist whether a biosimilar version currently exists, since the timeline and price impact can differ from the patent cliff pattern described above for small-molecule drugs.